Meaxin

Imatinib, the active ingredient in Meaxin, is a tyrosine kinase inhibitor presented as an unspecified-strength tablet for oral use. It is employed in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients, targeting abnormal cellular signaling pathways that drive malignant growth.

GNH USA supplies Meaxin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality-assured products that meet European regulatory standards and providing reliable efficient logistics through global distribution.

Imatinib acts on specific tyrosine kinases that are central to the pathogenesis of certain hematologic and solid tumours.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long-term survival in patients with BCR-ABL positive disease. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth and delays disease progression in patients with KIT or PDGFRα mutations. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): provides disease control as part of combination therapy in adult patients.

Imatinib may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea - Fatigue - Diarrhea

Serious or Rare Side Effects: - Hepatotoxicity - Severe neutropenia - Cardiac failure

Patients receiving Meaxin should be monitored regularly for safety and efficacy.

- Blood counts: perform complete blood count monitoring at baseline and periodically during therapy. - Liver function: assess hepatic enzymes before initiation and during treatment. - Cardiac assessment: evaluate cardiac function in patients with pre‑existing heart disease. - Hypersensitivity: discontinue if signs of severe allergic reaction occur. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store below 25°C: keep in the original pack, protect from moisture.

Imatinib has several drug‑interaction considerations that may affect its plasma concentration or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin) – may reduce therapeutic efficacy. - QT‑prolonging agents – may increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP2C8 inhibitors (e.g., gemfibrozil) – may modestly raise imatinib levels. - Proton pump inhibitors – may affect gastric pH and drug absorption. - Anticoagulants (e.g., warfarin) – may require INR monitoring for potential interaction.